{
    "clinical_study": {
        "@rank": "47139", 
        "brief_summary": {
            "textblock": "OBJECTIVES: I.  Evaluate the safety of ascending doses of CPX administered to adult patients\n      with mild cystic fibrosis.\n\n      II.  Evaluate the pharmacokinetics of ascending doses of CPX in this patient population."
        }, 
        "brief_title": "Phase I Randomized Study of CPX for the Treatment of Adult Patients With Mild Cystic Fibrosis", 
        "completion_date": "October 1999", 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled, dose escalation\n      study.\n\n      There are 7 experimental cohorts, each treated with a different oral dose of CPX or placebo.\n       Within each cohort, 4 patients receive a single dose of CPX and 1 patient receives placebo.\n       Each patient is monitored 24 hours postdose. Escalation to the next dose level for each\n      subsequent cohort begins only after the safety data obtained from the previous cohort is\n      reviewed and found not to limit dose escalation.\n\n      All patients return for a follow up evaluation 1 week after dosing."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n          -  Mild cystic fibrosis\n\n          -  Not pregnant or nursing Negative pregnancy test"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "35", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004428", 
            "org_study_id": "199/13364", 
            "secondary_id": "SCICLONE-FDA-OP-97-1"
        }, 
        "intervention": {
            "intervention_name": "CPX", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "cardiovascular and respiratory diseases", 
            "cystic fibrosis", 
            "genetic diseases and dysmorphic syndromes", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "SciClone Pharmaceuticals", 
            "last_name": "Eduardo Martins", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004428"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "SciClone Pharmaceuticals", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "September 1997", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2000"
    }, 
    "geocoordinates": {}
}